A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma

Jonathon B. CohenDepartment of Hematology and Medical Oncology, Emory University – Winship Cancer Institute, Atlanta, GA, USA; Correspondence[email protected]

Kami J. MaddocksDivision of Hematology, The Ohio State University James Comprehensive Cancer Center, Columbus, OH, USA

Ying HuangDivision of Hematology, The Ohio State University James Comprehensive Cancer Center, Columbus, OH, USA

Beth A. ChristianDivision of Hematology, The Ohio State University James Comprehensive Cancer Center, Columbus, OH, USA

Samantha M. JaglowskiDivision of Hematology, The Ohio State University James Comprehensive Cancer Center, Columbus, OH, USA

Christopher R. FlowersDepartment of Hematology and Medical Oncology, Emory University – Winship Cancer Institute, Atlanta, GA, USA;

Kristie A. BlumDivision of Hematology, The Ohio State University James Comprehensive Cancer Center, Columbus, OH, USA

show all

References

Mahadevan D, Stejskal A, Cooke LS, et al. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2012;18:2210–2219.
PubMed Web of Science ®Google Scholar
Manfredi MG, Ecsedy JA, Chakravarty A, et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res. 2011;17:7614–7624.
PubMed Web of Science ®Google Scholar
Qi W, Cooke LS, Liu X, et al. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol. 2011;81:881–890.
PubMed Web of Science ®Google Scholar
Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237 – investigational Aurora A kinase inhibitor – in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2014;32:489–499.
PubMed Web of Science ®Google Scholar
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
PubMed Web of Science ®Google Scholar
Friedberg JW, Mahadevan D, Cebula E, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014;32:44–50.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date